The Company develops and commercializes biomaterials, implantable medical devices, and preserves and distributes human tissues for cardiovascular and vascular transplant applications.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
First of all, the bioglue and tissue preservation services will only become more valuable in the future. The demand for such things will only increase with the population, and although the share price has fallen, the true value of the company will eventually be recognized. This, however, is only my first impression of the company and is merely my own personal opinion. Take from it what you will.
Cryolife also seems focused on putting their products in more doctors and specialists hands. The most recent presentation at the Sidoti's Forum shows their intent to more aggressively market their goods. The 51 person sales team has been aimed directly at cardiac and vascular surgeons. Management also seem s focused on protecting/expanding their core markets.
I believe we will see a turnaround by next quarter with continuous growth for a long while thereafter. Let's just hope there isn't another lawsuit filed against them over bad tissue again.
Outperform 1Y.
Were 2002-2005 poor income statements driven by legal issues?I need to look into these guys more. Their fundamentals look good now, but a few years ago they looked a bit different. I want to find out what the turn around was.